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ABSTRACT 
 
Wenqi Pan: Modulation of p53 signaling in an APT121 induced prostate cancer 
model 
(Under the Direction of Dr. Yanping Zhang) 
 
Recently, an APT121-induced prostate cancer mouse model was generated, 
in which Rb and its family members, p107 and p130, are inhibited, therefore 
leading to initiation and progression of prostate cancer. In the APT121 prostate 
cancer model, germline deletion of p53 has been shown to accelerate epithelial 
tumors as well as stromal tumors induced by paracrine stress signals from 
epithelial cells. However, given that human cancer is often the result of a 
somatic mutation rather than a germline mutation, the model described above 
cannot fully mimic the human situation. To address this issue, we have 
generated a mouse model harboring a somatic deletion of p53 in prostate 
epithelial cells. Through the development of a pre-clinical mouse model that 
more closely recapitulates the human disease, we are able to further explore 
the function of p53 signaling in response to Rb inhibition. Moreover, to 
investigate the potential therapeutic effects of p53 on prostate cancer, we 
utilized a p53 knock-in mouse model, p53ER, in which inactive p53 can be 
restored to its active state by tamoxifen treatment. Our study shows that 
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somatic deletion of p53 accelerates tumor progression and confirms that the 
stromal tumors observed in the previous report are indeed caused by paracrine 
signaling from epithelial cells. 
In the second part of our study, we focused on novel p53 signaling which 
has been reported to play a critical role in maintaining cell homeostasis after 
ribosomal stress. Disruption of the binding of ribosomal proteins (RP) and 
Mdm2 (a primary inhibitor of p53) in the Mdm2 point-mutation mouse model 
Mdm2C305F, has been shown to attenuate p53 signaling in Myc-induced 
lymphoma. This suggests that RP-Mdm2-p53 signaling could be a general 
tumor suppressor pathway activated in response to a variety of oncogenic 
stresses. To investigate this possibility, we crossed Mdm2C305F mice with 
APT121 mice. Our results showed that disruption of the RP-Mdm2-p53 pathway 
does not accelerate prostate tumorigenesis induced by APT121. Instead, the 
p19Arf-Mdm2-p53 pathway is the major player in response to Rb inhibition.  
All these studies have revealed the importance of p53 in the APT121 mouse 
model of prostate cancer. 
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CHAPTER ONE 
INTRODUCTION 
Prostate Cancer in Humans 
Prostate cancer is the second leading cause of cancer death in American men, behind 
only lung cancer. According to the American Cancer Society, about 217,730 new cases of 
prostate cancer were diagnosed in the United States in 2010, and 32,050 men died of 
prostate cancer. About 1 man in 6 will be diagnosed with prostate cancer during his lifetime 
(American cancer society: Cancer facts and figures 2010). Although the majority of patients 
initially respond well to androgen ablation, eventually nearly all men with advanced prostate 
cancer progress to hormone-refractory prostate cancer (HRPC). At this stage, chemotherapy 
may be used to extend survival, yet no curable therapeutic option is available (1). Despite the 
magnitude of the statistics, the underlying causes of prostate cancer remain elusive mainly 
due to the heterogeneity of genetic alterations found in the tumors (2). Several tumor 
suppressor genes have been implicated including Rb (Retinoblastoma) (3) and p53 (also 
known as protein 53 or tumor protein 53) (4). 
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APT121 Mouse Model of Prostate Cancer 
Rb and its family members p107, and p130 control the G1 to S-phase transition of the 
cell cycle primarily by interacting with the E2F family of transcription factors(5). Rb recruits 
chromatin-remodeling proteins, such as histone deactylases and histone methyl-transferases 
to repress the transcriptional activation of E2F1 (6-8). It was reported that 27% of human 
prostatic adenocarcinomas lost one RB allele (9) and both reduced expression of Rb mRNA 
and pRb protein have been reported (10-11).  
Mice lacking the Rb gene die at around 13 days of gestation before the prostate forms 
(12). Mice heterozygous for Rb or chimeric for Rb develop only pituitary or thyroid tumors 
(13-15). Somatic deletion of Rb in mouse epithelial cells only leads to early stage of prostate 
cancer (16). This appears to be because of compensation by p107 and/or p130 in many 
murine cell types (17). 
To bypass the redundancy of p107 and p130 in mice while focusing on the function of the 
pRb family alone in the development of prostate cancer, the APT121 prostate cancer mouse 
model was generated by Dr. Terry Van Dyke’s lab. APT121 is a truncated SV40 large T antigen 
(maintains the first 121 NH2-terminal amino acids; T121) under the probasin promoter. The 
transgene binds Rb and its family members, p130 and p107, and is specifically expressed in 
prostate epithelium (Figure 1A). When Rb is suppressed, E2F1 is activated and cells become 
tumorigenic. As early as 8 weeks of age, the prostates of APT121 mice exhibit dysplasia. 
APT121 mice show mouse prostatic intraepithelial neoplasia (mPIN) by 12 weeks old, 
characterized by tufting epithelial layers that form cribriform patterns. The prostates of APT121 
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develop micro-invasive adenocarcinomas by 16 weeks old, characterized as epithelial cells 
breaking through the basement membrane into the stroma (Figure 1B) (18) 
When APT121 mice are crossed with p53-/- mice, stromal tumors, identified as the 
presence and introductal growth patterns of stromal cells (Figure 2A and 2B), were greatly 
accelerated by p53 haploinefficiency.  Stromal tumors occur as early as 5 months old in 
APT121;p53+/- mice. In contrast, stromal tumors occur only randomly and much later in 
APT121;p53+/+ mice (Figure 2A) (18).  
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Figure 1.  APT121 mouse prostate cancer model (18).  
A. A diagram of APT121 mouse model: a truncated SV40 large T antigen under probasin 
promoter. The expression of the transgene is targeted to mouse prostate epithelial cells. The 
transgene is studied in the B6D2F1 mouse.  
B. Histological pictures demonstrated the progression of tumors in APT121 mice at 2 months 
(Dysplasia), 3 months (mPIN) and 4 months (Adenocarcinoma) of age. 
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Figure 2. Progression of epithelial tumor and stromal tumor in APT121;p53-/- mice (18). 
A. A diagram of p53 status and tumor progression in APT121 mice. p53 heterozygousity does 
not affect the onset of epithelial tumors, yet it accelerates the onset of stromal tumors with 
tumors appearing in mice by 5 month of age. APT121;p53+/- mice die around 7 months due to 
the enlargement of tumors. Both epithelial and stromal tumors are greatly advanced in 
APT121;p53-/- mice and mice die around 5 months of age.  
B. Large tumors in APT121;p53 -/- mice are comprised of extensive stromal component. Star 
indicates the stromal regions of tumors. 
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p53ER Mouse Model 
p53ER mice were generated by Gerard Evan lab (19). The hormone-binding domain of 
the modified estrogen receptor, ERTAM (20) was fused to p53 at the its’ 3'-end (Figure 3A). In 
the absence of 4-hydroxytamoxifen, p53m/m mice are similar to p53 null mice. Both develop 
tumors of the similar incidence and spectrum, though the onset of tumors in the p53ER/ER mice 
was slightly delayed (Figure 3B).  
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Figure 3. A diagram of the p53ERm allele (19) 
The ligand binding domain of estrogen receptor is fused to the 3’ end of p53 allele. Without 
tamoxifen, p53 is inactive. With tamoxifen, p53 is active.  
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RP-Mdm2-p53 Signaling Pathway 
p53 is well known as the guardian of the genome. Under stress such as DNA damage, 
oncogenic stress and hypoxia, p53 is stabilized and activated, resulting in the induction of a 
variety of downstream signaling pathways, including cell cycle arrest, apoptosis, DNA repair 
and senescence (21). Under normal condition, the level of p53 is kept low mainly by its 
inhibitor, Mdm2 (mouse double minute 2). The C-terminus of Mdm2 has an intrinsic E3 ligase 
activity which promotes the ubiquitiation and degradation of p53. The N-terminus of Mdm2 
binds to the transactivation domain of p53 and inhibits the recruitment of co-activators. 
Additionally, Mdm2 is directly transactivated by p53, thereby forming an Mdm2-p53 feedback 
loop to maintain cellular homeostasis (22). p53 has been found to be mutated in about 50% 
of human tumors, indicative of its importance in tumorigenesis (23). In addition to mutation of 
p53 directly, overexpression of Mdm2 can also cause tumors (24). 
The ribosome is the ‘factory’ for protein synthesis. The mammalian 80S ribosome is 
comprised of a large 60S and a small 40S ribosomal subunit. The 60S large subunit contains 
5S, 5.8S, and 28S rRNAs and around 47 large ribosomal proteins (RPL). The 40S small 
subunit contains 18S rRNA and around 32 small ribosomal proteins (RPS). Ribosomal 
subunits are made in the nucleolus and exported to the cytoplasm for the assembly of 
ribosomes. Ribosomal biogenesis requires balanced expression between rRNAs and 
ribosomal proteins, processing of rRNA precursors into mature rRNAs and assembly of 40S 
and 60S ribosomal subunits into 80S ribosome (25). When any of these steps are disrupted, 
for instance, via drug-treatment with mycophenolic acid (MPA) (26), actinomycin D (Act D)(27) 
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or 5-fluorouracil (5-FU) (28), ribosomal stress is induced. In addition to drug treatment, 
changing cell culture conditions, such as serum starvation and contact inhibition(29), or 
overexpression of nucleostemin or the dominant negative mutant Bop1(30) can also induce 
ribosomal stress.  
Under ribosomal stress, free forms of RPs (RPL and RPS), including L11 (31-32), L23 
(33-34) , and L5 (27), S7 (35) enter the nucleoplasm to interact with the zinc finger domain of 
Mdm2. This binding by L11, L23 or L5 inhibits MDM2's E3 ligase function, resulting in p53 
accumulation and activation (Figure 4). Knockdown of L11 and L5 does not induce a p53 
response, whereas knockdown of L23 does induce a p53 response. This indicates that these 
ribosomal proteins function similarly as well as distinctly to transmit ribosomal stress to the 
Mdm2-p53 pathway.  
S7 forms a ternary complex with Mdm2 and p53. Mdm2 can target S7 for ubiquitination, 
and MdmX (homolog of Mdm2) enhances the inhibition of Mdm2 by S7 (36). L26 also binds 
the zinc finger domain of mdm2 and besides that, L26 binds to the 5′ untranslated region 
(UTR) of p53 mRNA and augments its translation. The binding between Mdm2 and L26 
promotes the ubiquitination and degradation of L26 and therefore, weakens p53 
augmentation by L26 (37).  
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Figure 4. Diagram of RP-Mdm2-p53 signaling (38).  
Under normal conditions, large and small ribosomal subunits are assembled in the nucleolus 
(NO) and then exported to the cytoplasm (CP) for protein synthesis. However, under 
nucleolar stress, the balance between rRNA and ribosomal proteins (RPL and RPS) is 
disrupted. Free forms of ribosomal proteins are released from the NO to the nucleoplasm (NP) 
and bind to Mdm2. p53 is thereby activated and stabilized. Excess free forms of ribosomal 
proteins can also be released from cytoplasmic ribosomes and then enter the NP, interacting 
with Mdm2.  
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Mdm2C305F Knock-in Mouse Model 
In vitro data have shown that mutation of the zinc-coordinating cysteine (C) residues to 
phenylalanine (F) disrupts Mdm2’s interaction with L11 and L5 while retaining interaction with 
L23 (Figure 5). As a result, The MDM2C305F mutant is attenuated in mediating p53 
degradation after ribosomal stress (39). Based on in vitro data, our lab generated the 
Mdm2C305F/C305F knock-in mouse (40). And the characterization of Mdm2C305F knock-in mouse 
and Eu-Myc study are also done by a former lab member, Dr. Everardo Macias. 
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Figure 5. A diagram showing that a point mutation of Mdm2 disrupts its binding to 
ribosomal proteins L11 and L5 (40) 
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The Mdm2C305F mutation disrupts L5 and L11 binding (40) 
Previous study also investigated the binding activity of the Mdm2C305F mutant protein. 
Mouse embryonic fibroblasts (MEFs) were used for an immunoprecipitation-coupled western 
blot (IP-western) assay (40). When cell lystates were immunoprecipitated with anti-Mdm2 
antibody and then immunoblotted with anti-L5 and anti-L11 antibody, L5 and L11 were 
present in the Mdm2+/+ but not in the Mdm2C305F/C305F immunoprecipitates (Figure 7A). 
Mdm2C305F was still able to bind p53.  Because the anti-Mdm2 antibody (clone 2A10) affects 
the binding between Mdm2 and L23, we cannot evaluate the interaction of L23 with Mdm2 
using immunoprecipitation. We can however immunoprecipitate with anti-L23 antibody and 
then detect Mdm2 by western blotting. As shown in Figure 7B, L23 still binds to Mdm2C305F. 
The result is consistent with previous in vitro studies (39). 
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Figure 6.  Mdm2C305F mutant protein does not bind to L11 and L5 (40)  
A. Mdm2+/+ and Mdm2m/m MEFs were treated with 5 nM Act D. Cell lysates were 
immunoprecipitated with anti-Mdm2 antibody and to detect Mdm2, p53, L5 and L11 as 
indicated. 5% of total IP lysate is used as loading control.  
B. MEFs were treated as in (A), and cell lysates were analyzed as indicated. 
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Mdm2C305F mutation attenuates p53 response to ribosome biogenesis stress (40) 
Ribosomal stress induces releasing free forms of PRs, such as L11 and L5. L11 and L5 
can bind to Mdm2 and thereby, leads to p53 stabilization and activation. Since the Mdm2C305F 
mutant protein cannot bind to L5 and L11 as shown in figure 6, it is expected that the p53 
response would be attenuated after ribosomal stress. To assess this, Mdm2+/+, Mdm2+/C305F, 
and Mdm2C305F/C305F MEFs were either untreated or treated with a low dose of actinomycin D 
( 5nM Act D). Mdm2+/+ MEFs exhibited the highest induction of p53, compared to Mdm2+/C305F 
showing intermediate induction of p53, and Mdm2C305F/C305F with the lowest induction of p53 
(Figure 9A). Two other drug, 5-FU and MPA, are also known to induce ribosomal stress. MEF 
cells were treated with these two drugs to further confirm that p53 induction was attenuated 
in Mdm2C305F/C305F MEFs. Figure 9B show that again the p53 response is attenuated in a gene 
dosage dependent manner. Taken together, the data show that the p53 response to 
ribosomal stress is attenuated in Mdm2C305F MEFs (40). 
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Figure 7. Mdm2C305F MEFs exhibit attenuated p53 response to ribosome biogenesis 
stress (40).  
A. MEFs were either mock treated or treated with 5 nM Act D for 12 hr and then harvested for 
western blotting analysis.  
B. MEFs were treated with 1 μM 5-FU or 2 μM MPA for 12 hr and examined for p53 protein 
level by western blotting. 
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Myc-induced lymphomagenesis is accelerated by Mdm2C305F mutation (40) 
Translocation (t8;14) of Myc into or close to Ig loci is often observed in Burkitt’s B cell 
lymphoma (41). To mimic this in the mouse model, the Myc gene was coupled to an Emu 
immunoglobulin heavy chain enhancer, resulting in the overexpression of Myc in the B cell 
lineage (42). Eμ-myc mice die of B cell lymphoma and the median survival is 20 weeks. The 
Eμ-Myc;Mdm2+/C305F mice had a median survival of about 15 weeks, while the survival of 
Eμ-Myc;Mdm2C305F/C305F mice was reduced to a median of 9 weeks (Figure 10A). Tumors 
from the Eμ-Myc;Mdm2C305F/C305F mice were morphologically similar to those from 
Eμ-Myc;Mdm2+/+ mice (Figure 10B) (40). Given that Myc upregulates ribosomal biogenesis 
by interacting with all three RNA polymerases (43), these findings established the 
RP-Mdm2-p53 signaling as a genuine barrier against Myc-induced tumors. 
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Figure 8. Myc-induced lymphomagenesis is accelerated by Mdm2C305F mutation (40) .  
A. Survival of Eμ-Myc transgenic mice. Eμ-Myc;Mdm2+/+ (+/+, n = 24), Eμ-Myc;Mdm2+/m (+/m, 
n = 27), and Eμ-Myc;Mdm2m/m (m/m, n = 18) mice.  
B. Graph shows the lymphomas in a 58-day old Eμ-Myc;Mdm2m/m mice. 
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RP-Mdm2-p53 functions in a pattern similar to p19Arf-Mdm2-p53 in response to Myc 
Eμ–myc transgenics that were wild-type for p19Arf displayed a mean survival of 20 
weeks (42), while Eμ–myc transgenics heterozygous for p19Arf displayed a mean survival of 
11 weeks. Eμ–myc;p19Arf −/− mice die soon after birth in some offspring, and of those that 
survived initially, all died of lymphoma by 8 weeks of age (44)(Figure 8A). Tumors from 
Eμ–myc;p19Arf −/− mice were phenotypically indistinguishable from those from wild-type 
Eμ–myc transgenics. Noticeably, this pattern of tumor acceleration is very similar to the 
accelerated tumorigenesis observed in mice harboring the Mdm2C305 mutation in the Eμ–myc 
background (40)(Figure 8B). 
 
 
 
 
 
 
 
 
 
 
 
 
                             27  
Figure 9. Myc-induced tumorigenesis is accelerated by loss of ARF (44). 
Survival of Eμ-Myc transgenic mice. Eμ-Myc; ARF+/+ (ARF+/+, n = 31), Eμ-Myc; ARF+/− 
(ARF+/−, n = 85), and Eμ-Myc; ARF−/− (ARF−/−, n = 20) mice. Lymphoma was documented in 
all the animals. 
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CHAPTER TWO 
Targeted p53 deletion in APT121-initiated epithelial cells accelerates prostate 
cancer development that can be reversed by p53 restoration 
 
Abstract 
In the APT121 mouse model, Rb and its family members, p107 and p130, are 
inactivated specifically in prostate epithelial cells by expression of  APT121, an SV40 T 
antigen N-terminal fragment placed under regulation of the prostate 
epithelium-specific probasin promoter. It has been shown that APT121 transgenic mice 
develop prostatic intraepithelial neoplasia (mPIN), which further progresses into 
adenocarcinomas, and that this phenotype is accelerated by additional germline 
mutation of p53. However, prostate cancer is a disease more commonly associated 
with somatic mutations. Thus, we sought to investigate the role of somatic p53 
deletion in the development of prostate epithelial tumors. Here, we generated 
APT121;p53cf/f;Pb-Cre mice, in which the expression of APT121 and deletion of p53 occur 
simultaneously and specifically in the prostate of compound male mice at 6 weeks of 
age, as a preclinical animal model to both genetically and biologically emulate human 
prostate cancer. We show that deletion of p53 significantly accelerated prostate 
adenocarcinoma formation as well as the development of stromal tumors through a 
                             30  
mechanism that favors cell proliferation without affecting apoptosis. In addition, we 
took advantage of the previously generated p53ER mouse model where tamoxifen 
treatment re-establishes wild-type p53 function and developed APT121;p53ER/- mice to 
evaluate the consequence of restoration of p53 in prostate cancer cells. We show that 
reinstating p53 function by treating APT121;p53ER/- mice with tamoxifen resulted in 
decreased proliferation and increased apoptosis in the prostate, and significantly 
reduced tumor progression. Together, our data suggest that p53 plays a crucial role in 
prostate cancer initiation and progression and that therapies focusing on restoring 
p53 activity in epithelial cells could be an attractive approach to not only prevent 
malignant progression but also to delay the onset of prostate stromal tumors.  
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Introduction 
Prostate cancer is the second most common cancer among men. 25 to 50% of human 
prostate adenocarcinomas harbor aberrations in the Retinoblastoma (Rb) pathway. Rb is a 
tumor suppressor that binds to and represses the transcriptional activity of E2F family 
transcription factors that control the G1-S cell cycle transition. Phosphorylation of Rb by 
Cdk4/6-Cyclin D or Cdk2-Cyclin E releases Rb from the E2F complex, allowing 
transactivation of E2F target genes to occur. Rb inactivation is common in prostate cancer 
and generally precedes somatic alterations affecting the tumor suppressor gene p53 (45). 
Functional interactions between the two major tumor suppressor genes appear to directly 
influence tumor development in the mouse prostate (46). In particular, mutations of the p53 
gene are frequently associated with metastasis and an androgen depletion–independent 
phenotype in prostate cancer (47). 
Targeted inactivation of p53 in a murine model of prostate cancer was found to induce 
mouse Prostatic Intraepithelial Neoplasia (mPIN) but failed to progress to invasive carcinoma, 
indicating that loss of p53 may be a synergistic rather than an initiative event in promoting 
prostate tumorigenesis (48). On the other hand, deletion of both the Rb and p53 genes in 
mice resulted in rapid development of invasive and metastatic prostate cancer (49). Further 
studies indicated that the cell origin of prostate cancer associated with p53 and Rb deficiency 
is likely to be stem/progenitor cells that control luminal and neuroendocrine differentiation 
(50). 
The APT121;p53+/- and APT121;p53-/- mouse models revealed that these animals 
                             32  
experienced a great susceptibility to the development of oversized tumors comprised of 
adenocarcinomas and a large amount of abnormal stromal hyperproliferation (18, 51). 
However, germline mutation in the p53 gene does not seem to be an early event in prostate 
tumorigenesis; rather, it seems to be associated with the development of malignant 
progression. Thus, we proposed to investigate whether somatic inactivation of p53 in the 
prostate epithelium of APT121 mice alters the onset of adenocarcinomas and whether it 
participates in the development of stromal tumors. 
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Results 
Prostate epithelial-specific deletion of p53 accelerates adenocarcinoma development 
and induces stromal tumors in APT121-induced prostate cancer 
Prostate cancer is mostly associated with somatic gene mutations rather than germline 
gene mutations. In this context, results obtained from various mouse models have shown that 
complete ablation of p53 in mice may influence tumor development by altering the cell 
microenvironment. Thus, we sought to provide a preclinical system that could better simulate 
the human disease by generating a mouse model with prostate-specific somatic deletion of 
p53. We generated APT121 compound mice carrying a probasin-driven Cre/loxP system (52) 
to obtain conditional ablation of p53 expression. We bred the previously developed p53cf/f 
conditional knockout mice (53) with Probasin-Cre transgenic mice (Pb-Cre) (48), which 
express the Cre transgene in the epithelial cells of the prostate beginning at the onset of 
puberty around 6 weeks of age. The p53cf/f;Pb-Cre mice were then crossed with APT121 mice 
to generate APT121;p53cf/f;Pb-Cre compound mice. Thus, expression of APT121 and deletion 
of p53 occur simultaneously and in the same cellular compartment in the compound mice at 6 
weeks of age. 
We established tumor appearance by harvesting prostates from wild type, APT121, and 
APT121;p53cf/f;Pb-Cre mice every four weeks beginning at 8 weeks of age. To evaluate tumor 
progression, hematoxylin and eosin staining (H&E) of tissue sections was used. All groups of 
mice were monitored daily for signs of morbidity and prostate cancer development. None of 
the wild type littermates developed neoplasias during the course of these studies (Table 1). 
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However, consistent with previous reports (18), the APT121 mice developed mPIN at 12 weeks 
(75% incidence), which further transformed into adenocarcinomas by 4 months of age (75% 
incidence) (Table 1). The APT121;p53cf/f;Pb-Cre mice displayed a shorter latency for tumor 
development as reflected by the appearance of mPIN at 8 weeks with a 66% incidence. At 3 
months, APT121;p53cf/f;Pb-Cre mice had already developed adenocarcinomas with an 87.5% 
incidence, and by 5 months we observed 100% incidence of stromal neoplasias, consistent 
with a previous study of the APT121; p53-/- mouse prostate model (51). Interestingly, in the 
presence of wild type p53 APT121 prostates did not show stromal tumors until later in life, after 
11 months, and with a low incidence (30%) (Table 1). The survival rate correlated with the 
malignancy and progression of the tumors, as all of the APT121;p53cf/f;Pb-Cre mice died or 
had to be sacrificed by 5-6 months due to the tumor burden (Table 1 and Figure 10B). This 
phenotype was not apparent in mice harboring wild-type p53 (APT121 and WT mice) (Table 1 
and Figure 10A). H&E staining of wild type prostates from 5-month old animals exhibited 
normal prostate acini architecture arranged in a lobular configuration, consisting of a single 
layer of luminal cells and a layer of epithelial cells surrounded by a basement membrane 
separating the prostate gland from the stroma. The stroma, in turn, is formed by two to three 
layers of smooth muscle with loose connective tissue found between the glands (Figure 10C). 
APT121 prostates showed adenocarcinomas with the classic “acinar type” phenotype in which 
the tumor is thought to arise from or recapitulate prostatic acini (Figure 10D). The acinar type 
is characterized by back-to-back proliferation of small- to intermediate-sized tumor acini with 
scant to moderate intervening stroma. No stromal tumors were detected in APT121 prostates 
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at this age. In contrast, the APT121;p53cf/f;Pb-Cre compound mice displayed 
poorly-differentiated adenocarcinomas with infiltration of the prostate acina into the 
fibromuscular stroma and multiple areas where the basal cell layer was absent, highlighting 
the invasive and malignant nature of these tumors (Figure 10E). Furthermore, the enlarged 
tumors were comprised of a large portion of stromal neoplastic cells that expanded into the 
glands (Figure 10F).  
Altogether, these data indicate that deletion of p53 in the epithelium of APT121 prostates 
results in early tumor onset with features of malignancy, invasion, and the occurrence of 
stromal neoplasia, the latter of which is likely induced by a paracrine effect from the abnormal 
epithelial cells to the surrounding mesenchymal tissue. This is consistent with the hypothesis 
that in APT121;p53+/- prostates, the oncogenic stress in prostate epithelium signals a 
mitogenic stimulation to the mesenchyme leading to the development of stromal tumors (51). 
It is of note that prostatic stromal tumors have also been found in humans (54-56).  
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Table 1. Early onset of prostate cancer in APT 121 ; p53cf/f ; Pb-Cre mice 
 
Genotype mPIN Adenocarcinoma Stromal tumor Survival 
Wild-type None (0/4) None (0/5) None (0/5) >18 months 
APT121 3 months (3/4) 4 months (6/8) >11 months (3/10) >15 months 
APT121; p53cf/f; 
Pb-Cre 
2 months (4/6) 3 months (7/8) 5 months (9/9) 5-6 months 
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Figure 10. Deletion of p53 in prostate epithelium accelerates both adenocarcinoma 
and stromal tumors in APT121 mice. 
 Gross anatomy of prostates from APT121   (A) and   APT121;p53cf/f; Pb-Cre  (B) prostate 
gland and associated seminal vesicles.. APT121; p53cf/f; Pb-Cre prostate displays solid tumors, 
dramatically enlarged with important vasculature. Hematoxilin and Eosin (H&E) staining of 
wild-type prostate (C) shows normal gland architectures.and the inset illustrates the single 
layer of epithelial cells in the gland. (D)  APT121 prostate shows well-differentiated 
adenocarcinoma, and the inset points out to the intact basement membrane. (E)  
APT121;p53cf/f; Pb-Cre prostate displays poorly-differentiated  adenocarcinoma. The arrow 
indicates the increased proliferation and loss of basement membrane that resulted in 
invasion to the stroma.  (F) A representative stromal tumor found in APT121;p53cf/f; Pb-Cre 
prostate, the (*) demarks the stromal neoplasia and the inset shows the expansion of stromal 
cells inside of the epithelial gland and the lack of organization of the mesenchymal cells.  All 
histological analysis was done in mice of  5 month old. 
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Adenocarcinomas developed in APT121;p53cf/f;Pb-Cre compound mice are not derived 
from neuroendocrine cells 
Some prostate cancer mouse models develop tumors classified as adenocarcinomas, 
while other models form neuroendocrine carcinomas. It has been previously demonstrated 
that in some mouse models of prostate cancer, the origin of the tumor and the progression of 
the disease are influenced by the mouse strain background. One example is the widely used 
transgenic adenocarcinoma mouse prostate (TRAMP) model. While TRAMP mice with a 
C57BL/6J background develop adenocarcinomas, TRAMP mice with an FVB background 
have a significantly shorter lifespan than TRAMP-C57BL/6J mice due to the rapid 
progression of neuroendocrine carcinomas forming from bipotential progenitor cells at early 
stages of prostate tumorigenesis(57). Consistent with these studies, the APT121;p53cf/f;Pb-Cre 
mice, which have a genetic background similar to that of the FVB-TRAMP mice, have a 
shorter lifespan due to the size and the malignancy of the prostate tumors. We performed a 
series of immunohistochemistry (IHC) stainings to define the APT121;p53cf/f;Pb-Cre prostate 
tumor cell origin. We first confirmed that the transgene T121 expression was confined to the 
epithelial compartment (Figure 11A), ruling out the possibility of leaky expression of the 
transgene. IHC staining showed that the APT121;p53cf/f;Pb-Cre neoplasias were positive for 
the androgen-receptor (AR), which is a marker expressed in both prostate epithelial and 
mesenchymal connective cells but not in neuroendocrine cells (Figure 11B). Figure 11C 
shows that cytokeratin18/8, a marker restricted to luminal epithelial cells, was confined to the 
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epithelium of prostate tumors, as expected. Lastly, synaptophysin (SYN), a specific marker 
for neuroendocrine cells, was negative in all samples tested (Figure 11D), thus ruling out the 
possibility that the tumors detected in APT121;p53cf/f;Pb-Cre prostates were of neuroendocrine 
origin as was reported for the FVB-TRAMP model (57). Together, these evidences indicate 
that the tumors formed in APT121;p53cf/f;Pb-Cre mice can be classified as adenocarcinomas. 
Additionally, we assessed the invasive capacity of the adenocarcinomas by staining for 
α-smooth actin (SMA), a marker found at the fibromuscular stromal cell layer that surrounds 
the tumors. We observed a loss of this marker at a large portion of the area surrounding the 
APT121;p53cf/f;Pb-Cre tumors, indicating that the stromal layer was disrupted in this area, 
enhancing the tumors’ ability to migrate (Figure 11E and 11F). This loss of α-smooth actin 
highlights the invasive nature of the APT121;p53cf/f;Pb-Cre tumors. 
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Figure 11.  APT121; p53cf/f; Pb-Cre cancer cells do not derive from neuroendocrine 
cells.   
(A) T121 IHC staining: Using the SV40 T antigen mouse mAb, the expression of T121 is 
restricted to the prostate epithelial cells of APT121; p53cf/f; Pb-Cre mice. (B) The 
Androgen-receptor (AR) IHC staining illustrates that the expression of this marker in the 
glandular epithelium and the stroma is conserved. (C) Immunofluorescence for cytokeratins 
18/8 (CK18/8) shows adequate distribution of luminal epithelia cells. (D) Synaptophysin (SYN) 
specifically identifies neuroendocrine cells, which were not detected in any of the compound 
mice tumors. (E) α-smooth actin (SMA) is a marker of fibromuscular cells and underlies the 
basement membrane of the glandular tissue. (F) As demarked by the arrow and the pointed 
line, the fibromusular cells distribution becomes lose with areas of complete absence of the 
expression of this marker, indicating the micro-invasive nature of these tumors.  
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Prostate epithelial-specific deletion of p53 does not affect apoptosis but enhances 
proliferation in APT121-induced prostate cancer 
The data presented here demonstrate that specific deletion of p53 in prostate epithelial 
cells results in reduced tumor latency and increased malignancy. In order to understand the 
probable mechanism leading to increased tumor growth in APT121;p53cf/f;Pb-Cre prostate 
neoplasms, we quantified the rates of proliferation and apoptosis by immunohistochemical 
staining. In APT121 prostates, the quantity of proliferating epithelial cells was 49%, as 
measured by Ki67 staining (a marker of cell proliferation) (Figure 12A and 12C). The 
APT121;p53cf/f;Pb-Cre prostate epithelial cells were significantly more proliferative than the 
APT121 cells, with 73% of cells staining positive for Ki67 (Figure 12B and 12C). To measure 
the rate of apoptosis in the prostate tumor cells, a TUNEL assay (terminal deoxynucleotidyl 
transferase–mediated dUTP-biotin nick end labeling) was used. No significant difference in 
apoptosis was observed between APT121;p53cf/f;Pb-Cre prostates and APT121 prostates 
(14.2% and 12.2% apoptotic cells, respectively), (Figure 12D-F). These data indicate that 
p53 function in the prostate epithelial tissue is important in the regulation of cell proliferation 
but is not required for modulation of apoptosis. 
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Figure 12. p53 deletion in ATP121 prostate induced adenocarcinomas are the results of 
increased proliferation but not apoptosis. 
(A-B)  Representative Ki67 staining from 5 month-old mice of the indicated genotype. Brown 
staining indicates proliferating cells. (C) Average % proliferating cells (Ki67-positive) ± SEM 
from 5 month-old mice of the indicated genotype. n=5 for each genotype. At least five 
independent fields consisting of a total of at least 1,000 cells from each prostate sample were 
counted. *p < 0.05 as assessed by Student’s t test. (D-E) Representative TUNEL assay from 
5 month-old mice of the indicated genotype. Apoptotic cells are stained purple. (F)  Average 
% apoptotic cells (TUNEL-positive) ± SEM from 5 month-old mice of the indicated genotype. 
n=5 for each genotype. At least five independent fields consisting of a total of at least 1,000 
cells from each prostate sample were counted.  
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Restoration of p53 function in APT121; p53ER/- mice delays the onset of APT121-induced 
prostate cancer by reducing proliferation and increasing apoptosis 
We have demonstrated that p53 plays a pivotal role in tumor progression of 
APT121-induced prostate cancer. To further investigate the function of p53 in tumor 
suppression, we took advantage of an inducible-p53 mouse model, p53ER (19). These mice 
have inactive p53 in the absence of tamoxifen, and upon inoculation with this drug, the 
activity of wild-type p53 is reinstated. We generated and selected APT121;p53ER/- males to 
evaluate whether the malignant tumor phenotype could be reversed or delayed by restoring 
p53 function. Without tamoxifen injection, APT121;p53ER/- mice resemble APT121;p53-/- mice. 
After tamoxifen injection, the APT121;p53ER/- prostate epithelial cells become heterozygous for 
p53 (APT121;p53+/-). Considering that APT121;p53ER/- mice die around 4 months of age due to 
oversized prostate tumors, we began tamoxifen treatments at 2 months. Tamoxifen or oil 
(mock treatment) were introduced intraperitoneally (i.p) every 3 days during a 30-day period 
(a total of 10 applications). The mice were euthanized within 3 days after the last treatment. 
Prostate samples were formalin-fixed and paraffin-embedded for histological examination. As 
shown in Table 2, oil-injected APT121;p53ER/- mice exhibited a 100% incidence of 
adenocarcinomas. In contrast, the tamoxifen-injected APT121;p53ER/- mice exhibited a 
dramatic drop in the incidence of adenocarcinomas; instead, the majority of these mice (4 out 
of 6) showed only mPIN (Table 2). Notably, all APT121;p53-/- mice developed 
adenocarcinomas (measured at the same time), regardless of tamoxifen treatment. 
Histochemically, the oil-injected APT121;p53ER/- mice showed clear development of prostate 
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adenocarcinoma, whereas the tamoxifen-treated APT121;p53ER/- mice displayed benign, 
well-differentiated mPIN (Figure 13A and 13B). The control APT121;p53-/- mice displayed, as 
expected, prostate adenocarcinoma with all treatments (Figure 13C and 13D). To examine 
how reinstating p53 expression in the prostate cells affects tumor onset, prostate sections 
were assessed by immunohistochemistry for the expression of Ki67, a proliferation marker, 
and with a TUNEL assay. Restoration of p53 expression by tamoxifen injection resulted in a 
significant decrease in proliferation and increase in apoptosis in the prostate of APT121;p53ER/- 
mice: Proliferating cells decreased from 44% to 28% of total cells, and apoptotic cells 
increased from 8% to 18% (Figure 4M and 4N, open bars). This effect was not observed in 
control APT121;p53-/- mice (Figure 4M and 4N, filled bars). Representative IHC images were 
shown in Figure 13E-H for Ki67 staining and in Figure 13I-L for TUNEL staining. In summary, 
our results indicate that the expression of wild-type p53 is essential for preventing malignant 
initiation and progression in prostate tumors, and that restoration of p53 function in these 
tumor cells can effectively reverse malignant prostate adenocarcinoma progression and 
abolish stromal tumor formation. 
                             48  
Figure 13. Restoration of p53 expression in APT121; p53ER/- epithelial cells prevents 
prostate malignant progression  
Representative H&E staining of prostate sections from mice of the indicated genotypes and 
treatments. (A) APT121; p53ER/- prostate shows adenocarcinomas upon Oil injection. APT121; 
p53ER/- prostate shows mPIN upon tamoxifen inoculation that results in restoration of p53 
expression (B). Both oil-injected and tamoxifen-injected APT121; p53-/- prostates show 
adenocarcinoma with stromal tumor phenotype.(C and D).  Representative Ki67 staining 
from mice of the indicated treatment. Brown staining indicates proliferating prostatic cells.of 
oil or tamoxifen-treated APT121; p53ER/-  prostates (E and F) and that of oil or 
tamoxifen-treated APT121; p53-/-  prostates (G and H). Representative TUNEL staining from 
mice of the indicated treatment. Purple staining indicates apoptotic cells of oil or 
tamoxifen-treated APT121; p53ER/-  prostates (I and J) and that of oil or tamoxifen-treated 
APT121; p53-/-  prostates (K and L). 
(M)  Average % Ki67-positive cells ± SEM from mice of the indicated treatment. n=5-6 for 
each genotype. At least five independent fields consisting of a total of at least 1,000 cells 
from each prostate sample were counted. **p < 0.01 as assessed by Student’s t test. (N)  
Average % TUNEL-positive cells ± SEM from mice of the indicated treatment. n=5-6 for each 
genotype. At least five independent fields consisting of a total of at least 1,000 cells from 
each prostate sample were counted. **p < 0.01 as assessed by Student’s t test.  
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Table 2. Restoration of p53 function in APT 121 ; p53TAM/- mice delays the onset of 
prostate tumors. 
 
Genotype IP injection 
mPIN Adenocarcinoma Stromal Tumor 
APT121; p53ER/- Oil 0/5 5/5 2/5 
APT121; p53ER/- Tamoxifen 4/6 2/6 0/6 
APT121; p53 -/- Oil 0/4 4/4 2/4 
APT121; p53 -/- Tamoxifen 0/4 4/4 1/4 
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Discussion 
Prostate cancer is a devastating disease that affects adult men and is the second most 
common cancer among this population. It is predicted that 1 out of 6 men will be diagnosed 
with prostate cancer during their lifetime (58). Over the last few years, many research groups 
have developed animal models to analyze the stages and progression of the disease. 
However, the heterogeneous nature of prostate cancer has proven difficult to recapitulate. 
One useful model to study the progression of prostate cancer is the APT121 transgenic mouse. 
In this model, the expression of Rb and its family members, p107 and p130, is inhibited upon 
expression of the N-terminal fragment of the SV40 T antigen, which is regulated in this model 
by the prostate epithelial-specific probasin promoter. APT121 mice have normal expression of 
p53, making these mice suitable for studying the role of Rb as a cancer initiator to which 
other mutations can be added in order to understand the multistage nature of the disease.  
In this study, we have deleted p53 somatically in prostate epithelial cells in order to better 
recapitulate the progression of human prostate cancer. In particular, we took advantage of 
the APT121 mouse model to mimic the initial aberrant event in the development of prostate 
neoplasia and then induced somatic inactivation of p53 by generating APT121;p53cf/f;Pb-Cre 
compound animals. Here, we were able to demonstrate that APT121;p53cf/f;Pb-Cre mice, 
similar to the previously reported APT121;p53-/- mice, develop adenocarcinomas much earlier 
and at a higher incidence than APT121 transgenic mice. Furthermore, the 
APT121;p53cf/f;Pb-Cre tumors also recapitulated the appearance of stromal tumors, which 
have been previously described in the APT121;p53-/- mouse model. Stromal tumors, although 
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rare, are a clinical challenge during the development of human prostate malignancies, due to 
the uncommon pattern of proliferation that results in various histological presentations. These 
tumors, also known as Stromal Tumors of Uncertain Malignant Potential (STUMP), present a 
unique pattern of proliferation in these stromal cells, which are behaviorally and histologically 
distinct from benign hyperplasias and whose behavior cannot be predicted by histological 
appearance. In this case, we found that the APT121;p53cf/f;Pb-Cre tumors were greatly 
enlarged, in part due to uncontrolled proliferation and expansion of the mesenchymal 
compartment (Figure 1E-F). These results indicate that p53 deletion in prostate epithelium 
with a compound loss of Rb function is sufficient to drive prostate tumorigenesis and 
stromal-associated malignant transformation. Furthermore, the data presented here suggest 
that the stromal tumors observed in a previous study (18, 51) in APT121;p53+/- and 
APT121;p53-/- prostates could be the result of paracrine signals induced by the epithelial cells 
to the stroma, rather than a consequence of cell-autonomous loss of p53 in the stroma. 
However, whether this is actually true remains to be determined.  
Another interesting finding from this study is that tumors derived from 
APT121;p53cf/f;Pb-Cre mice display increased proliferation compared to APT121 tumors, but 
without noticeable changes in apoptotic levels. p53-independent apoptosis in prostate tumors 
has been demonstrated in the APT121 model (18). Here, we found evidence that p53 ablation 
enhances the over-proliferative phenotype induced by loss of Rb function in prostate 
epithelial cells, which may cause the early onset of prostate cancer. Furthermore, we 
evaluated the dependency of the APT121 tumors on p53 activity by utilizing the APT121;p53ER/- 
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mouse model. In this case, restoration of p53 activity by administration of tamoxifen resulted 
in decreased proliferation and increased apoptosis in the prostate and significantly reduced 
tumor progression. In this scenario, p53-dependent apoptosis clearly play a role in the 
prevention of the malignant phenotype, which is different from the results obtained with 
APT121;p53cf/f;Pb-Cre mice. A possible explanation is that in APT121;p53cf/f;Pb-Cre mice, 
prostate cells are able to adapt to the absence of p53, whereas in tamoxifen-treated 
APT121;p53ER/- mice, rapid restoration of p53 induces apoptosis. It is likely that epithelial 
deletion of the p53 gene is sufficient to drive malignant transformation and the development 
of surrounding stromal neoplasias. As the cells undergo aberrant proliferation, there may be 
selection pressure for cells that have acquired further mutations leading to genomic instability, 
resulting in the loss of other genes involved in apoptosis including p53. In summary, our 
results emphasize the relevance of p53 in mediating prostate cancer and its collaboration 
with Rb inactivation. Our data suggest that delivery of p53 in the epithelial prostate gland 
could be a potential therapeutic strategy for treatment of prostate cancers.  
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Materials and methods 
Mouse breeding strategies 
To study the somatic deletion of p53 in APT121 mice, APT121 females were crossed with p53cf/f 
males to create and select for APT121;p53 cf/+ mice; p53cf/f females were then crossed with 
Pb-Cre males to generate and select for Pb-Cre;p53cf/+ males. The APT121;p53cf/+ females 
were crossed with Pb-Cre;p53cf/+ males to generate APT121;p53cf/f;Pb-Cre mice and littermate 
controls without Pb-Cre. Similarly, to study the effect of p53 restoration in APT121 mice, the 
mice were mated with p53ER/- and with p53-/- mice. The offspring generated by the breeding, 
APT121;p53ER/- and APT121;p53-/- mice, were intraperitoneally injected with oil or tamoxifen 
(1mg/mouse) once every 3 days for 30 days to restore p53 activity. Prostate tissues were 
harvested for analysis of tumor development and for measuring proliferation and apoptosis. 
 
Histopathology  
Prostate samples were fixed overnight in 10% phosphate-buffered formalin, transferred to 
70% ethanol, and then embedded into paraffin. Samples were sectioned for 10 successive 
layers at 5-µm intervals and stained with H&E for histopathologic examination. 
 
Immunohistochemistry 
Immunohistochemical analysis was performed on formalin-fixed, paraffin embedded tumor 
sections. Detection of antibodies for Ki67 (550609, BD Pharmigen, San Diego, CA) , T121 
(Ab-2, Calbiochem, San Diego, CA), Cytokeratin 8/18 (GP11, Progen, Heidelberg, 
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Deutschland, Germany), α-smooth muscle actin (A2547, Sigma-Aldrich, St. Louis, MO), 
androgen receptor (PG-21, Upstate, Temecula, CA) and synaptophysin (611880, BD 
Pharmigen, San Diego, CA) was done using the Vector ABC Elite kit and a Vector 
3,3'-Diaminobenzidine kit for substrate detection (Vector Laboratories, Burlingame, CA). 
Apoptotic levels were assessed using the terminal deoxynucleotidyl transferase–mediated 
dUTP-biotin nick end labeling (TUNEL) assay (ApopTaq Peroxidease in situ Kit from 
Chemicon) following the manufacturer’s instructions. Cells from 5 random areas of each 
prostate tumor sample were counted, and the percentage of positively stained cells 
compared to the total number of cells was calculated. Differences in proliferation or apoptosis 
levels among mice of all genotypes were evaluated using a t-test (P < 0.05 was considered of 
statistical significance). 
 
 
 
 
 
CHAPTER THREE 
 
The in vivo Role of the RP-Mdm2-p53 Pathway in Signaling Oncogenic Stress 
Induced by pRb Inactivation and Ras Overexpression 
 
Abstract 
The Mdm2-p53 tumor suppression pathway plays a vital role in regulating cellular 
homeostasis by integrating a variety of stressors and eliciting effects on cell growth 
and proliferation. Recent studies have demonstrated an in vivo signaling pathway 
mediated by ribosomal protein (RP)-Mdm2 interaction that responds to ribosome 
biogenesis stress and evokes a protective p53 reaction. It has been shown that mice 
harboring a Cys-to-Phe mutation in the zinc finger of Mdm2 that specifically disrupts 
RP L11-Mdm2 binding are prone to accelerated lymphomagenesis in an oncogenic 
c-Myc driven mouse model of Burkitt's lymphoma. Because most oncogenes when 
upregulated simultaneously promote both cellular growth and proliferation, it 
therefore stands to reason that the RP-Mdm2-p53 pathway might also be essential in 
response to oncogenes other than c-Myc. Using genetically engineered mice, we now 
show that disruption of the RP-Mdm2-p53 pathway by an Mdm2C305F mutation does not 
accelerate prostatic tumorigenesis induced by inactivation of the pRb family proteins 
(pRb/p107/p130). In contrast, loss of p19Arf greatly accelerates the progression of 
prostate cancer induced by inhibition of pRb family proteins. Moreover, using 
ectopically expressed oncogenic H-Ras we demonstrate that p53 response remains 
intact in the Mdm2C305F mutant MEF cells. Thus, unlike the p19Arf-Mdm2-p53 pathway, 
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which is considered a general oncogenic response pathway, the RP-Mdm2-p53 
pathway appears to specifically suppress the tumorigenesis induced by oncogenic 
c-Myc.  
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Introduction 
p53 is a critical tumor suppressor gene which is mutated in about 50% of all human 
tumors (23). It is often referred to as the guardian of the genome because under various 
cellular stress conditions such as DNA damage, oncogenic insult, and hypoxia, p53 is 
stabilized and activated, inducing cell cycle arrest, apoptosis, DNA damage repair, 
senescence, and a variety of other protective responses (21). Under normal conditions, p53 
levels are kept low, mainly through inhibition by Mdm2 (mouse double minute 2). The 
C-terminus of Mdm2 has an intrinsic E3 ligase activity, which promotes the ubiquination and 
degradation of p53. The N-terminus of Mdm2 binds to the transactivation domain of p53 and 
inhibits the recruitment of co-activators. Mdm2 is also directly transactivated by p53, 
therefore forming an Mdm2-p53 feedback loop to maintain cellular homeostasis (22).  
Recently several ribosomal proteins, including L11 (59), L5 (34) and L23 (33, 60) have 
been shown to bind Mdm2 at its zinc finger domain. Under normal conditions, these proteins, 
along with rRNAs, form the large and small subunits of ribosomes in the nucleolus (25). 
However, under conditions of ribosome stress, free forms of ribosomal proteins are released 
into the nucleoplasm and bind to Mdm2, leading to p53 stabilization and activation (61). A 
cancer-associated cysteine-to-phenylalanine point mutation in the zinc finger domain of 
Mdm2 causes disruption of L11 and L5 binding to Mdm2 (62), and based on this in vitro data, 
we previously generated a knock-in mouse with the Mdm2 C305F mutation. Mdm2C305F 
mutant mice maintain a normal p53 response to DNA damage, but are deficient in p53 
induction in response to induced ribosomal stress (40). 
Intriguingly, the Mdm2 C305F mutation was recently shown to significantly accelerate B cell 
lymphomagenesis in an Eμ-Myc induced mouse model of B cell lymphoma (40). The ability of 
Myc to promote cell growth and proliferation is closely linked to its role in regulating ribosomal 
biogenesis. Myc facilitates the recruitment of Pol I to rDNA promoters (63-64), promotes the 
transcription of ribosomal proteins by activating Pol II (65-68), and activates Pol III-mediated 
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transcription of 5S rRNA and tRNA (69). In the case of Eμ-myc-induced lymphoma, ribosomal 
proteins L11 and L5 are unable to bind and suppress Mdm2C305F in Eμ-Myc;Mdm2C305F/C305F 
mice, and as a result activation of p53 is attenuated and B cell lymphomagenesis is 
accelerated (40). These findings established the RP-Mdm2-p53 pathway as a genuine barrier 
to Myc-induced tumorigenesis. 
Another well-studied pathway suppressing Myc-induced B cell lymphoma is 
ARF-Mdm2-p53 signaling. Loss of p19Arf results in a similar acceleration of Eμ-Myc induced 
lymphomagenesis to that caused by Mdm2 C305F mutation (40, 44). ARF can physically 
interact with Mdm2, and therefore, releasing p53 from Mdm2-mediated degradation and 
transactivation silencing (70-73). Besides Myc, ARF can also induce p53 in response to E2F1 
and Ras. E2F1 directly activates human p14Arf at transcriptional level(74).Overexpression of 
Ras transforms p19 null mouse embryo fibroblasts (MEFs) via bypassing p53-mediated 
checkpoint control (75). Ras induces a cell cycle arrest in wild type murine keratinocytes, 
which mediated by an increased expression of p19Arf (76). While ARF-Mdm2-p53 signaling 
acts downstream of a variety of oncogenes, that ARF-independent induction of p53 can also 
occur upon oncogenic stress. For instance, when expressing T121, a transgene inhibiting 
pRb and therefore activating E2F1, in choroid plexus (CP) epithelial cells, p19Arf is 
dispensable for p53-mediated tumor suppression and apoptosis (77). Ras induction of 
p53-dependent cell cycle arrest in murine keratinocytes also does not rely on ARF (78). The 
alternative pathway leading to p53 activation is unclear. Given that oncogenes promote cell 
proliferation and/or growth associated with elevated protein synthesis, ribosomal biogenesis 
might be generally disrupted in response to oncogenic stress. Therefore, RP-Mdm2-p53 
signaling may play a general role in responding to oncogenic stress and suppressing 
tumorigenesis like it does in Myc-induced B cell lymphoma. 
 E2F1 has been reported to bind rRNA promoter and enhance its activity (79). Similarly, in 
the yeast Saccharomyces cerevisiae, Ras/TOR induces Sfp1 which is required for 
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Ifh1(transcriptional co-activator) binding to RP gene promoters, a network linking cell growth 
to ribosomal biogenesis (80). In the mammalian cell, maRas-PI3K-Akt-mTOR is well-known 
to promote protein translation and cell growth (81). All these cellular process may induce 
ribosomal stress, which leads to activation of RP-Mdm2-p53 signaling. Hence, the current 
study focuses on examining whether the RP-Mdm2-p53 pathway may act as a general 
response to oncogenic stress by utilizing models of pRb inactivation and Ras activation.  
Specifically, to investigate whether disruption of RP-Mdm2-p53 signaling accelerates 
tumorigenesis induced by inactivation of pRb, we crossed Mdm2C305 mice with a 
well-characterized mouse prostate cancer model called APT121, in which a truncated SV40 
large T antigen under the probasin promoter leads to pRb inactivation in prostate epithelium 
(18, 82), to see if tumor progression is accelerated by Mdm2C305.To investigate whether 
disruption of RP-Mdm2-p53 signaling accelerates tumorigenesis induced by Ras activation, 
we used normal mouse keratinocytes and mouse embryonic fibroblasts (MEFs) systems to 
measure the ribosomal proteins and compare p53 response signaling. 
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Results 
Mdm2 C305F mutation causes reduced prostate size and slows the progression of 
APT121-induced prostate cancer 
Inactivation of p53 alone in the murine prostate leads to the development of prostatic 
intraepithelial neoplasia (PIN) with no progression to invasive carcinoma, suggesting that 
loss of p53 may be a complementary rather than initiating event in promoting prostate 
tumorigenesis (83). Previous findings have also shown that attenuation of p53 signaling 
through loss of one allele of p53 does not accelerate the onset of epithelial tumors in an 
APT121-induced mouse model of prostate cancer, but induces a stromal tumor phenotype, 
which is characterized by extensive stromal cell presence and intraductal growth patterns 
(51). The Mdm2 C305F mutation, which disrupts the binding of ribosomal proteins L11 and L5 
to Mdm2 (40), causes an attenuation of p53 signaling, suggesting that the Mdm2 C305F 
mutation may alter the progression, rather than initiation, of prostate tumorigenesis in a 
similar way as p53 heterozygosity.  
To examine the importance of the RP-Mdm2-p53 pathway in APT121-induced prostate 
cancer, we generated APT121;Mdm2+/+ and APT121;Mdm2C305F/C305F mice and non-tumorigenic 
control Mdm2+/+ and Mdm2C305F/C305F mice. The progression of tumorigenesis was then 
compared among these mice to see if disruption of RP-Mdm2-p53 signaling altered the 
development of cancer. 
APT121;Mdm2+/+ and APT121;Mdm2C305F/C305F mice  did not exhibit noticeable differences 
in general appearance or body weight. We compared the size of prostate glands isolated 
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from mice at 6 months of age. Surprisingly, the prostates from Mdm2C305F/C305F mice were 
generally smaller than those from Mdm2+/+ mice, and consistent with this finding, the 
prostates from APT121;Mdm2C305F/C305F mice were smaller than those from APT121;Mdm2+/+ 
mice (Figure 14A). The average weight of 11 Mdm2C305F/C305F prostates was 0.088 grams 
while that of 12 Mdm2+/+ prostates was 0.117 grams. The average weight of 13 
APT121;Mdm2C305F/C305F prostates was 0.172 grams and that of 9 APT121;Mdm2+/+ prostates 
was 0.221 grams (Figure 14B). The differences in weight were statistically significant, with *p 
< 0.05 and **p < 0.01 respectively.   
We next examined prostate histology by hematoxylin and eosin (H&E) staining on 
paraffin-embedded prostate samples isolated from 6 month-old mice. None of the 
Mdm2C305F/C305F or Mdm2+/+ mice exhibited abnormality in their prostates (Figure 14C). 
Prostate adenocarcinoma, defined as penetration of malignant prostate epithelial cells 
through the basement membrane of the prostate gland into the surrounding stroma, was 
often observed in APT121;Mdm2+/+ mice, while the majority of the APT121;Mdm2C305F/C305F mice 
only developed mPIN (mouse prostatic intraepithelial neoplasia), with few examples of 
well-differentiated adenocarcinoma (Figure 14C). As shown in Table 3, 71.4% of 
APT121;Mdm2+/+ mice developed adenocarcinomas compared with only 37.5% of 
APT121;Mdm2C305F/C305F mice. Thus the progression from mPIN to adenocarcinoma is 
decreased by Mdm2C305F mutation. 
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Figure 14. Mdm2 C305F mutation causes reduced prostate size and slows the 
progression of APT121-induced prostate cancer.  
A. Photographs showing representative prostates from 6 month-old mice of the indicated 
genotypes.  
B. Average prostate mass ± SD from 6 month-old mice of the indicated genotypes. Mdm2+/+ 
(n=12), Mdm2C305F/C305F (n=11), APT121;Mdm2+/+ (n=9), and APT121;Mdm2C305F/C305F (n=13) . * 
p < 0.05 and ** p < 0.01  as assessed by Student’s t test.  
C. Representative H&E staining of prostate sections from 6 month-old mice of the indicated 
genotypes demonstrating histology associated with the indicated stages of tumor progression. 
Scale bar was shown in the first picture and all pictures were taken at the same 
magnification. 
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Table 3. Summary of prostate tumor stages in 6 month-old Mdm2+/+, Mdm2C305F/C305F, 
APT121;Mdm2+/+ , and APT121; Mdm2C305F/C305F  mice. 
 
 Mdm2+/+ Mdm2C305F/C305F APT121;Mdm2+/+ APT121; Mdm2C305F/C305F 
Total 8 7 7 8 
Normal 8 7 0 0 
Dysplasia 0 0 0 0 
mPIN 0 0 2 5 
Adenocarcinoma 0 0 5 (71.4%) 3 (37.5%) 
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Mdm2 C305F mutation decreases proliferation but does not affect apoptosis of 
APT121-induced prostate cancer 
To address the differences in tumor progression described above, the proliferation and 
apoptosis of isolated prostate tissues were examined by immunohistochemical analysis. Cell 
proliferation was assessed by ki67 staining. Prostates from Mdm2C305F/C305F or Mdm2+/+ mice 
had few proliferating cells, while prostates from APT121;Mdm2+/+ and APT121;Mdm2C305F/C305F 
mice were highly proliferative (Figure 15A). As quantified in Figure 15B, there was no 
statistically significant difference in the percentage of ki67 positive cells between Mdm2+/+ and 
Mdm2C305F/C305F prostates (3.64% and 3.39%, respectively). However, there was a statistically 
significant difference in the percentage of ki67 positive cells between APT121;Mdm2+/+  and 
APT121;Mdm2C305F/C305F prostates (64.6% and 48.8%, respectively). 
To examine apoptosis in the prostates of the various transgenic mice, TUNEL (terminal 
deoxynucleotidyl transferase–mediated dUTP-biotin nick end labeling) immunohistochemical 
analysis was carried out. Representative pictures of TUNEL-stained sections are shown in 
Figure 15C. Prostates isolated from APT121;Mdm2+/+ and APT121;Mdm2C305F/C305F mice had a 
much higher percentage of TUNEL-positive apoptotic cells than those of Mdm2+/+ or 
Mdm2C305F/C305F mice (Figure 15D). However, there was no significant difference in apoptosis 
between APT121;Mdm2+/+ and APT121;Mdm2C305F/C305F prostates (5.59% and 6.51% 
respectively) or between Mdm2+/+ and Mdm2C305F/C305F  prostates (0.29% and 0.89% 
respectively). Taken together, these data suggest that the Mdm2C305F mutation may slow 
down the progression of prostate tumorigenesis by decreasing proliferation, rather than 
affecting the apoptosis of prostatic cells.  
Previous studies have shown that Myc can up-regulate ribosomal biogenesis (63-64) 
and that ribosomal protein expression is elevated during Myc-induced lymphomagenesis (40). 
To investigate whether APT121 induces increased expression of ribosomal proteins, total 
protein was isolated from prostate glands harvested from four mice of each genotype, and 
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expression of ribosomal protein L11 was examined by western blot. Unlike the situation in 
Myc-induced lymphomagenesis in which L11 was significantly increased in the presence of 
Myc (40), L11 was not induced by APT121 (data not shown), suggesting that APT121-induced 
prostate cancer does not cause ribosomal stress.  
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Figure 15. Mdm2 C305F mutation decreases proliferation but does not affect apoptosis 
of APT121-induced prostate cancer.  
A. Representative Ki67 staining of prostate sections from 6 month-old mice of the indicated 
genotypes. Brown staining indicates proliferating cells. Scale bar was shown in the first 
picture and all pictures were taken at the same magnification.  
B. Average % Ki67-positive cells ± SD from 6 month-old mice of the indicated genotypes. At 
least five independent fields consisting of a total of at least 1,000 cells from each prostate 
sample were counted. **p < 0.01 as assessed by Student’s t test.  
C. Representative TUNEL staining of prostate sections from 6 month-old mice of the 
indicated genotypes. Brown staining indicates apoptotic cells. Scale bar was shown in the 
first picture and all pictures were taken at the same magnification.  
D. Average % TUNEL-positive cells ± SD from 6 month-old mice of the indicated genotypes. 
At least five independent fields consisting of a total of at least 1,000 cells from each prostate 
sample were counted. (A – D) Mdm2+/+ (n=8), Mdm2C305F/C305F (n=7), APT121;Mdm2+/+ (n=7), 
and APT121;Mdm2C305F/C305F (n=9) mice were used.  
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Loss of p19Arf accelerates adenocarcinoma and stromal tumor development in 
APT121-induced prostate cancer 
While our data suggest that RP-Mdm2 signaling does not inhibit APT121-induced 
prostate cancer, previous findings have shown that both RP-Mdm2 and p19Arf-Mdm2 signal 
to p53 and function equivalently as barriers to suppress Myc-induced B cell lymphoma (40, 
44). ARF can be induced by a variety of oncogenes including Ras, Myc and E2F1, inhibiting 
Mdm2 and thereby activating p53 (74, 84-85). p53 is believed to play an important role in 
suppressing prostate cancers of higher tumor stage or androgen-independent tumors (86-87). 
However, it is unknown whether p19Arf-Mdm2-p53 signaling is needed for the suppression of 
APT121-induced prostate cancer. 
To examine the role of the p19Arf-Mdm2-p53 pathway in APT121-induced prostate 
cancer, we crossed APT121 with p19Arf-null mice. By 5 months of age, all APT121;p19Arf-/- 
mice developed adenocarcinomas, while the majority of the APT121;p19Arf+/+ mice only 
developed mPIN (Table 4). Furthermore, tumors from APT121;p19Arf-/- prostates were 
comprised of a large portion of stromal cells, which expanded not only outside of the 
epithelial glands, but inside the glands as well (Figure 16A). This phenotype was similar to 
what was defined as ‘stromal tumor’ in a previous study (51). The stromal tumor phenotype 
occurred at a high frequency (5 of 6 mice) in APT121;p19Arf-/- mice while it was not detected in 
APT121;p19Arf+/+ mice (Table 4).  
We further measured the proliferation and apoptosis rates of APT121;p19Arf+/+ and 
APT121;p19Arf-/- prostates by immunohistochemical analysis as mentioned above. 
APT121;p19Arf-/- prostates exhibited a higher rate of proliferation and no significant difference 
in apoptosis compared with APT121;p19Arf+/+ prostates (Figure 16B-C and 16D-E). Therefore, 
p19Arf-Mdm2-p53 signaling apparently inhibits the progression of APT121-induced prostate 
cancer by affecting cell proliferation. Taken together, these data suggest that the 
p19Arf-Mdm2-p53 pathway, rather than the RP-Mdm2-p53 pathway, is the main barrier to 
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suppress APT121-induced prostate cancer. 
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Figure 16. Effects of p19Arf loss on tumor progression in APT121-induced prostate 
cancer.  
A. Representative H&E staining of prostate sections from 5 month-old mice of the indicated 
genotypes. Stromal tumor was detected only in APT121;p19Arf-/- mice as indicated by asterisk. 
Scale bar was shown in the first picture and all pictures were taken at the same magnification. 
B. Representative Ki67 staining from 5 month-old mice of the indicated genotypes. Scale bar 
was shown in the first picture and all pictures were taken at the same magnification.  
C. Average % Ki67-positive cells ± SD from 5 month-old mice of the indicated genotypes. n=6 
for each genotype. At least five independent fields consisting of a total of at least 1,000 cells 
from each prostate sample were counted. Brown staining indicates proliferating cells. *p = 
0.01 as assessed by Student’s t test.  
D. Representative TUNEL staining from 5 month-old mice of the indicated genotypes. Scale 
bar was shown in the first picture and all pictures were taken at the same magnification.  
E. Average % TUNEL-positive cells ± SD from 5 month-old mice of the indicated genotypes. 
n=6 for each genotype. At least five independent fields consisting of a total of at least 1,000 
cells from each prostate sample were counted. Brown staining indicates apoptotic cells.  
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Table 4. Summary of prostate tumor stages in 5 month-old APT121;p19Arf+/+ and 
APT121;p19Arf-/- mice.  
 
 APT121;p19Arf+/+ APT121;p19Arf-/- 
Total 6 6 
Epithelial neoplasia mPIN 4 0 
 Adenocarcinoma 2 (33.3%) 6 (100%) 
Stromal tumor 0 5 (83.3%) 
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Activated Ras does not up-regulate the expression of ribosomal protein in mouse 
keratinocytes  
To further investigate if the RP-Mdm2-p53 signaling pathway is required for oncogenic 
Ras induction of p53, we examined its function in response to activation of H-Ras. 
Constitutively active mutant forms of the Ras family of small GTPases are found in 
approximately one-third of all human cancers. Active GTP-bound Ras stimulates numerous 
effector proteins to induce diverse downstream signaling events affecting cell growth, 
proliferation, differentiation, and apoptosis (88). Given that the Ras-PI3K-Akt-mTOR pathway 
promotes protein translation and cell growth in mammalian cells (89), we tested whether 
activated Ras could induce ribosomal stress and trigger the RP-Mdm2-p53 pathway.  
To investigate this possibility, we first examined whether Ras could up-regulate the 
expression of ribosomal proteins in four different mouse keratinocyte cell lines: BalMk2 
normal mouse keratinocytes with wild-type Ras, 308 benign mouse skin papilloma cells (90), 
CH72-T3 malignant mouse skin squamous cell carcinoma cells (91), and CC4A malignant 
mouse skin carcinoma cells all carrying an H-Ras mutation at codon 61 (92). We measured 
the protein level of ribosomal protein L11 by western blot. Compared with BalMK2 normal 
mouse keratinocytes that have wild-type Ras, Ras activation in 308, CH72-T3 or CC4A cell 
lines did not induce increased expression of ribosomal protein L11 (Figure 17A).  
 
Expression of activated Ras in Mdm2C305F mutant MEFs induces a normal p53 
response but does not up-regulate the expression of ribosomal proteins  
While the data from mouse keratinocytes suggested that activated Ras may not induce 
ribosomal stress, the cell lines could not fully address the function of RP-Mdm2-p53 signaling 
in response to Ras activation. In order to investigate whether the Mdm2C305F mutant protein, 
and thus decreased interaction between ribosomal proteins and Mdm2, could affect the p53 
response to Ras activation, early passage Mdm2+/+ and Mdm2C305F/C305F MEFs were stably 
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infected with retroviruses encoding either H-RasG12V (a constitutively active form of H-Ras) or 
an empty vector control. Ras is known to induce cellular senescence via an intact 
p19Arf-Mdm2-p53 pathway in murine cells (75, 84). Following infection with Ras virus, we 
observed comparable cell cycle arrest in Mdm2+/+ and Mdm2C305F/C305F MEFs as evidenced by 
a similar decrease in cell number (Figure 17B). Ras expression was confirmed by western 
blot analysis and was comparable in Mdm2+/+ and Mdm2C305F/C305F MEFs (Figure 17C).  
To determine the effect of Ras expression on ribosomal protein levels, cell lysates were 
immunoblotted for expression of L5 and L11. Expression of activated Ras did not upregulate 
L11 or L5 in Mdm2C305F/C305F or Mdm2+/+ MEFs (Figure 17C, lane 1 versus lane 2, lane 3 
versus lane 4). To examine p53 response to Ras expression, cell lysates were also 
immunoblotted for p53. Ras induced p53 stabilization in both Mdm2C305F/C305F and Mdm2+/+ 
MEFs (Figure 17C, lane1 versus lane2, lane 3 versus lane4). p53 was induced to a similar 
extent in Mdm2C305F/C305F and Mdm2+/+ MEFs (Figure 17C, lane2 versus lane4), indicating that 
Mdm2C305F/C305F MEFs have a normal p53 response to Ras activation. These data suggest 
that Ras activation does not induce ribosomal stress in the cells tested, and that 
RP-Mdm2-p53 signaling may not be critical in response to Ras-induced oncogenic stress. 
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Figure 17. Activated Ras induces a normal p53 response but does not up-regulate 
ribosomal protein L11.  
A. Detection of L11 and β-actin by immunoblot analysis of total cellular lysate prepared from 
the indicated mouse karatinocyte cell lines. β-actin serves as a loading control.  
B. Representative phase-contrast images of Mdm2+/+ and Mdm2C305F/C305F MEFs stably 
infected with empty vector or H-Ras
G12V
 retroviruses.  
C. Detection of L11, L5, p53, H-Ras, and β-actin by immunoblot analysis of total cellular 
lysate prepared from the MEFs described in B. β-Actin serves as a loading control.  
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Discussion 
Recently several ribosomal proteins, including L11 (59), L5 (34) and L23 (33, 60) have 
been shown to bind Mdm2 at its zinc finger domain. Under conditions of ribosomal stress, 
free forms of ribosomal proteins are released into the nucleoplasm and bind to Mdm2, 
leading to p53 stabilization and activation (61). Interestingly, a cancer-associated 
cysteine-to-phenylalanine point mutation in the zinc finger domain of Mdm2 disrupts binding 
of L11 and L5 to Mdm2 (62), and Mdm2C305F mutant knock-in mice are deficient in p53 
induction in response to induced ribosomal stress (40).  
Additionally, the Mdm2 C305F mutation was recently shown to significantly accelerate B 
cell lymphomagenesis in an Eμ-Myc induced mouse model of B cell lymphoma (40, 42). The 
ability of Myc to promote cell growth and proliferation is closely linked to its role in regulating 
ribosomal biogenesis, and in the case of Mdm2C305F and Myc-induced lymphoma, ribosomal 
protein expression is elevated, however ribosomal proteins L11 and L5 are unable to bind 
and suppress Mdm2C305F, resulting in attenuation of p53 activation (40). These findings 
established the RP-Mdm2-p53 pathway as a genuine barrier to Myc-induced tumorigenesis. 
The current study examined whether the RP-Mdm2-p53 pathway acts as a general 
response to oncogenic stress by utilizing models of pRb inactivation and Ras activation. We 
now show that Mdm2 C305F mutation results in decreased prostate size and, unlike the 
situation in Myc-induced B cell lymphomagenesis (40), slows the progression of prostate 
tumorigenesis induced by inactivation of pRb family proteins in the well-characterized APT121 
mouse model of prostate cancer (18). Immunohistochemical analysis showed a significant 
decrease in the percentage of ki67-positive cells in prostates isolated from 
APT121;Mdm2C305F/C305F versus APT121;Mdm2+/+ mice, but no significant difference in TUNEL 
staining. These data suggest that the reduction in prostate size and slowed progression of 
prostate tumorigenesis induced by Mdm2 C305F mutation may be due to a defect in 
proliferation rather than an increase in cell death.  Moreover, unlike the situation in 
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Myc-induced lymphomagenesis in which ribosomal protein L11 expression was significantly 
increased (40), L11 expression was not induced by APT121 (data not shown), suggesting that 
APT121-induced prostate cancer does not cause ribosomal stress. Interestingly, 
Mdm2C305F/C305F mice exhibit smaller prostates than wild-type mice. Need to point out, except 
for the differences in size, the prostates from Mdm2C305F/C305F mice are completely normal in 
function and do not have any defects in prostate development. p53 has recently been 
reported to promote cell survival through induction of TIGAR (TP53-induced glycolysis and 
apoptosis regulator) (93). It is possible that disruption of RP-Mdm2-p53 signaling leads to 
slightly lower level of p53 in the Mdm2C305F/C305F prostates. Under normal condition, the 
slightly difference in p53 level may not be critical for cell proliferation and growth. However, 
under oncogenic stress such as pRb inhitition, lower p53 level may hinder cell proliferation in 
the Mdm2C305F/C305F prostates. 
With regard to Ras activation, we show that constitutively active mutant Ras does not 
up-regulate the expression of ribosomal proteins either in mouse keratinocyte cell lines or 
when overexpressed in Mdm2+/+ or Mdm2C305F/C305F MEFs. These data suggest that Ras 
activation does not induce ribosomal stress in the cells tested, and that RP-Mdm2-p53 
signaling may not be critical in response to Ras-induced oncogenic stress. 
While previous findings have shown that both RP-Mdm2 and p19Arf-Mdm2 signal to p53 
and similarly suppress Myc-induced B cell lymphoma (40, 44), our data presented here 
suggest that disruption of RP-Mdm2 signaling does not accelerates APT121-induced prostate 
cancer. However, loss of p19Arf accelerates adenocarcinoma and stromal tumor 
development in APT121-induced prostate cancer, and isolated APT121;p19Arf-/- prostates 
exhibited a higher rate of proliferation and no significant difference in apoptosis compared 
with APT121;p19Arf+/+ prostates. Thus, p19Arf-Mdm2-p53 signaling apparently inhibits 
APT121-induced prostate cancer progression by affecting cell proliferation. Furthermore, the 
phenotype observed in APT121;p19Arf-/- mice is consistent with that reported in a prior study 
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on APT121;p53-/- mice (51), confirming the importance of p19Arf-Mdm2-p53 signaling in tumor 
suppression of APT121-induced prostate cancer. 
 In conclusion, the present study suggests that the p19Arf-Mdm2-p53 pathway 
suppresses APT121-induced prostate tumorigenesis. p19Arf-Mdm2-p53 may be a general 
pathway to suppress a wide range of oncogenic assaults.. However, p19Arf is not required 
for p53 response to ribosomal stress while RP-Mdm2-p53 signaling is required (40). The lack 
of ribosomal stress observed upon pRb inactivation and Ras activation also suggests that the 
PR-Mdm2-p53 pathway may not be a general barrier to oncogenic stress, but rather a 
specific response to ribosomal stress induced by oncogenes such as Myc. It is likely that 
p19Arf and RP are induced by different cellular stress and therefore, binds to Mdm2 and 
activates p53，which emphasizes the importance of Mdm2 in mediating p53 response upon a 
variety of cellular stresses, such as oncogenic stress and ribosomal stress. 
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Materials and methods 
Ethics Statement 
This study is approved by the Institutional Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill. IACUC approval ID. 10-045.0. Mice were 
humanely euthanized by CO2 asphyxiation followed by a second method to ensure 
euthanasia. Mouse tumors and organs were fixed in formalin for histopathology and snap 
frozen for protein extraction. 
 
Mouse Breeding Strategies 
Derivation of APT121 (C57BL6/J;DBA2) transgenic mice was previously described (18). 
To study the effect of the RP-Mdm2-p53 pathway on prostate tumorigenesis, APT121 mice 
were mated to Mdm2C305F/C305F (C57BL6/J) mice that were generated and genotyped as 
previously described (40). We used standard breeding strategies to produce APT121;Mdm2+/+,  
APT121;Mdm2C305F/C305F and nontransgenic male littermates Mdm2+/+ and Mdm2C305F/C305F 
served as controls. To study the effect of the p19Arf-Mdm2-p53 pathway on prostate 
tumorigenesis, APT121 mice were mated to p19Arf-/- (C57BL6/J; Sv129) mice that were 
generated and genotyped as previously described (75). Mice harboring a homozygous 
deletion of p19ARF exon 1 were originally provided by C. J. Sherr and M. F. Roussel (St. Jude 
Children’s Hospital) and maintained in Terry Van Dyke’s lab (UNC-Chapel Hill). We used 
standard breeding strategies to produce APT121;p19ARF+/+ and APT121;p19ARF−/− mice. Mice 
were bred and maintained under a protocol (10-045.0) approved by the Institutional Animal 
Care and Use Committee at the University of North Carolina Animal Care Facility. Mice were 
humanely euthanized by CO2 asphyxiation followed by a second method to ensure 
euthanasia. Mouse tumors and organs were fixed in formalin for histopathology and snap 
frozen for protein extraction. 
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Measurement of prostate size 
Prostate tissues from 6 month-old APT121;Mdm2+/+  and APT121;Mdm2C305F/C305F mice as 
well as from their Mdm2+/+ and Mdm2C305F/C305F littermate controls were excised, 
photographed, and weighed. All procedures involving mice were done according to a protocol 
approved by the University of North Carolina Institutional Animal Care and Use Committee. 
 
Histopathology 
Prostate tissues from APT121;Mdm2+/+ and APT121;Mdm2C305F/C305F mice as well as from 
their Mdm2+/+ and Mdm2C305F/C305F non-tumorigenic littermate controls, were fixed overnight in 
10% phosphate-buffered formalin and then transferred to 70% ethanol. Samples were sent to 
the UNC Histology Core Facility for paraffin embedding. Paraffin blocks were sectioned at 
5-µm intervals for successive layers and stained with hematoxylin (Sigma-Aldrich, St. Louis, 
MO) and eosin for histopathology examination.  
 
Apoptosis analysis 
Apoptosis levels of mouse prostate sections were assessed by the terminal 
deoxynucleotidyl transferase–mediated dUTP-biotin nick end labeling (TUNEL) assay 
(ApopTaq Peroxidease in situ Kit, Millipore, Temecula, CA). A ratio of TUNEL-positive stained 
cells to total cells counted was calculated. Statistical significance in differences in apoptosis 
levels between mice with different genotypes was evaluated by Student’s t test (P < 0.05 was 
considered significant). 
 
Proliferation analysis 
    Ki67 immunohistochemical staining of mouse prostate samples was used to detect 
proliferating cells. Antigen retrieval for antibody on formalin-fixed paraffin sections was done 
by boiling paraffin samples in citrate buffer (pH 6.0) for 15 min. Endogenous peroxidase 
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activity was quenched by incubation in 3% H2O2 in methanol for 10 minutes. Antibody 
detection was done by using purified mouse anti-human Ki67 primary antibody (BD 
Pharmigen, San Diego, CA) and biotin-conjugated anti-mouse secondary antibody (Vector 
Laboratories, Burlingame, CA). An avidin-biotin-peroxidase kit (Vectastain Elite, Vector 
Laboratories) with diaminobenzidine was used as a chromogen. A ratio of positive stained 
cells to total cells was calculated. Statistical significance in differences in proliferation levels 
between mice with different genotypes was evaluated by Student’s t test (P < 0.05 was 
considered significant). 
 
Culture of cells  
Mouse keratinocyte cell lines and low-calcium culture media were provided by Dr. 
Marcelo Rodriguez-Puebla at North Carolina State University. MEF cells were isolated on 
embryonic day 13.5 (E 13.5) and cultured in DMEM (GIBCO, Carlsbad, CA) supplemented 
with 10% fetal bovine serum (GIBCO) and penicillin-streptomycin (GIBCO).  
 
Retroviral infection of MEF cells 
293 QBT cells (94) were transfected with plasmids: pVPack-Eco (viral coat protein 
plasmid for infecting mouse and rat cells), pVPack-Gag-Pol (viral protein plasmid) and pBabe 
or pBabe-H-Ras12V. Fugene HD kit was utilized for transfections, following manufacturer’s 
instructions (Roche diagnostics, Indianapolis, IN). Virus-containing medium from 293 QBT 
cells was filtered through a 0.45 µm syringe-tip filter and mixed with fresh medium at the ratio 
of 1:1. Polybrene was added to the mixed medium to a final concentration of 6 µg/ml. The 
medium from primary mouse embryo fibroblasts (MEF) cells was removed and replaced with 
virus-containing medium. MEF cells were infected with a retrovirus derived from 
pBabe-puro-H-Ras12V or empty vector as a control, and stable polyclonal populations were 
selected by puromycin resistance. 
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Protein detection  
Prostate tissues from APT121;Mdm2+/+ and APT121;Mdm2C305F/C305F as well as from their 
Mdm2+/+ and Mdm2C305F/C305F non-tumorigenic littermate controls were homogenized on ice 
and lysed in 0.5% NP-40 lysis buffer. Cultured cells (mouse keratinocytes and MEFs) were 
also lysed in 0.5% NP-40 lysis buffer. Total cellular lysates were run on a 12.5% 
SDS-polyacrymide gel followed by immunoblotting using standard procedures. Mouse 
monoclonal anti-p53 (NCL-505, Novocastra Laboratories, Newcastle upon Tyne, England) 
and anti-actin (MAB1501, Chemicon International, Temecula, CA) antibodies were 
purchased commercially. Rabbit polyclonal antibodies to L5 and L11 were produced as 
previously described (62). 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR 
Summary and Future Directions 
 
Role of p53 in APT121-initiated Prostate Cancer Model 
Previous study showed that loss of one or two alleles of p53 greatly accelerates the 
onset and progression of adenocarcinoma initiated by APT121 (18, 51). However, genome 
wide loss of p53 is known to cause tumors in a variety of systems, such as lymphomas and 
sarcomas, which makes efforts to study its role in a single tissue difficult and does not reflect 
the true nature of prostate cancer progression in humans. The previous comparisons of 
tumor latency and mouse lifespan upon p53 loss were all on germline knockout mutants. 
Therefore, it is necessary to re-evaluate these in the somatic mutation system. 
In this study, we generated a better pre-clinical mouse model for prostate cancer, in 
which pRb family members and p53 are somatically deleted in prostate epithelial cells. 
Deletion of p53 does accelerate the adenocarcinoma induced by APT121. p53 is intact in the 
stroma of APT121;p53cf/f;PbCre mice, yet tumors from APT121;p53cf/f;PbCre mice are 
comprised of a large component of stromal cells, the same phenotype was also observed in 
APT121;p53+/- and APT121;p53-/- mice in the previous study. In APT121; p53+/- mice, loss of 
heterozygosity (LOH) of p53 in the stroma happens before LOH of p53 in the epithelial cells 
induced by expression of T121 in the epithelia. It was hypothesized that there is a cell 
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non-autonomous signal between epithelia and stroma (51). However, lack of one functional 
copy of the p53 allele in the stromal cells may also promote LOH of p53 in stroma in the 
APT121p53 +/- mice in a cell-autonomous manner. To test this possibility, in the current study 
of APT121;p53cf/f;PbCre mice, p53 is only deleted in prostate epithelial cells while stromal 
tumors still occurred. This confirmed that the stromal expansion observed in APT121;p53-/- 
mice is caused by paracine signaling from epithelial cells per ce. However, the paracrine 
signaling remains unknown. It is also unknown that whether p53 in the stroma is loss or not 
due to selection pressure. One way to address this will be to use laser capture 
microdissection. 
 
In addition, It has also been shown that carcinoma-associated fibroblasts (CAFs) can 
accelerate the tumorigenesis in otherwise normal prostate epithelial cell layer (95). We would 
like to explore whether neoplastic or normal epithelial cells progress to more severe states 
through the influence of the supporting stromal cell layer. A useful system to study the 
mesenchymal-epithelial interactions is the tissue recombination procedure developed by 
Cunha and Lung (96). Briefly, mouse urogenital sinus mesenchyme (UGM) will be prepared 
from 16-day embryonic fetuses of pregnant APT121 (C57BL/6) that will be crossed to p53KO+/- 
(C57BL/6) male. The possible genotypes of the pups are: wild-type (WT), APT121, 
                             88  
APT121;p53KO+/- and p53KO+/-. Separation of urogenital sinus mesenchyma (UGM) will be 
dissected from urogenital sinuses as previously described (97). The adult bladder urothelium 
mice will be separated from the stroma. Epithelial tissue fragments will then be recombined 
with UGM in neutralized type I rat tail collagen gels as previously described (98). Tissue 
recombinants will be grafted beneath the renal capsule of adult homozygous Rag1-/- male 
mice which are immune deficient due to lack of matured T and B cells. Mice will be 
euthanized and the grafts harvested. Using this system, it will be possible to determine 
whether cancer-associated fibroblasts can stimulate the tumor progression of nearby 
epithelial cells. 
Our study confirmed that loss of p53 synergizes with loss of Rb to promote prostate 
tumorigenesis. However, it is unclear what downstream targets are disrupted by loss of p53 
in this prostate cancer model. mRNA microarray can be done to search for potential 
downstream genes by comparing APT121;p53cf/f;Pb-Cre tumors with APT121 tumors. Agilent 
mouse 4X44K Whole Mouse Genome Oligo Microarray Kit will be used. Real-time RT-PCR 
will be used to confirm gene expression difference. Western-blot will be done on prostate 
lysates to examine the protein expression of the whole prostate. Tissue microarrays (also 
TMAs) will also be done to immunodetect protein changes in situ.  
Loss of p53 often induces genome instability. To see whether this contributes to the 
tumor progression in our APT121 prostate model, we will measure the gene copy variation by 
CGH arrays (comparative genomic hybridization arrays). 5 months old is close to the terminal 
stage of for APT121;p53cf/f;Pb-Cre mice. Additional gene deletions may be accumulated due to 
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of tumor selection. Mouse Genomic CGH 4X44K arrays will be used on APT121;p53cf/f;Pb-Cre 
prostates of 5 months old to analyze copy number changes (gains/losses) caused by 
prolonged loss of p53 and Rb. 
    Tumors harboring p53 mutations are often more vascularized and correlate with poor 
prognosis for treatment (99). The significance of angiogenesis in prostate cancer is well 
established. Many studies have demonstrated its direct correlation with Gleason score, tumor 
stage, progression, metastasis and survival (100-102). From data mentioned above, it is 
obvious that tumors from APT121; p53cf/f; Pb-Cre mice are more vascularized than those from 
APT121 mice. To compare vasularization between APT121 and APT121; p53cf/f; Pb-Cre prostates 
immnodetection of CD31will be used to visualize vessel structure in our tumor samples. 
CD31 is also known as PECAM-1 (Platelet Endothelial Cell Adhesion Molecule-1). 
CD31-mediated endothelial cell-cell interactions are involved in angiogenesis. In addition, we 
will establish a collaboration with Dr. Paul Dayton at UNC to use his ultrasonic sound imaging 
system and targeted microbubble contrast agents as a non-invasive tool to image vessels in 
live murine prostate.  
 
RP-Mdm2-p53 Pathway in Signaling Oncogenic Stress 
Previous study showed that disruption of RP-Mdm2 binding accelerates B cell lymphoma. 
This was the first time that RP-Mdm2-p53 signaling has been proved as a novel barrier in 
response to oncogenic stress and leads us to question whether this signaling can play a 
general in tumor suppression. To investigate this idea, we used a mouse model of prostate 
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cancer, APT121, in which pRb and its family are inhibited. Our data demonstrated that 
disruption of RP-Mdm2 binding does not accelerate the prostate cancer. Instead, deletion of 
p19Arf greatly accelerates epithelial tumors and induces a unique stromal phenotype of 
APT121 prostate cancer as observed previously in p53-deficient background. Besides 
investigating tumors induced by inactivation of pRb, we also examined the function of 
RP-Mdm2-p53 in response to activation of Ras. Compared with Mdm2+/+ MEFs, 
Mdm2C305F/C305F MEFs maintain a normal and comparable p53 response when Ras is 
constitutively activate.  
 
The reason why RP-Mdm2-p53 plays a critical role in Myc induced B cell lymphomas but 
not in tumors induced by pRb inactivation is probably due to the lack of ribosomal stress in the 
latter one. Consistent with this concept, Ras activation does not upregulate ribosomal proteins 
either, and therefore, p53 signaling is intact regardless of the integrity of RP-Mdm2-p53 
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pathway. However, it is unknown whether this can be a rule to apply on all oncogenes, and 
consequently to determine if RP-Mdm2-p53 signaling is required or not for tumor suppression. 
One way to address this is to introduce a large panel of oncogenes individually into Mdm2+/+ 
and Mdm2C305F/C305F MEFs and then categorize them into two groups: those that upregulate 
ribosomal proteins and those do not upregulate ribosomal proteins. If the p53 response is 
attenuated in the former group while it remains intact in the latter group, we can conclude that 
RP-Mdm2-p53 is required only when a certain oncogene induces ribosomal stress, such as 
overexpression of ribosomal proteins. If not, the alternative explanation may be that functional 
RP-Mdm2-p53 signaling only suppresses tumor types that increase quickly in their volume, 
such as lymphoma, yet this signaling does not inhibit tumor types that take a long time to grow, 
such as prostate cancer.  
Another issue we ponder on is why Mdm2C305F/C305F mice exhibit a smaller prostate than 
wild-type mice. Mdm2C305F/C305F male mice are slightly smaller than their wild-type 
counterparts in the body size too, though the difference is not statistically significant (data not 
shown). Recently p53 has been reported to promote cell survival through induction of TIGAR 
(TP53-induced glycolysis and apoptosis regulator) (93). It is possible that Mdm2C305F/C305F 
mice have slightly lower level of p53 than is needed for normal cell growth and survival, and 
therefore, mice are slightly smaller in body size as well as some organs. To investigate this 
possibility, endogenous p53 level from tissues of Mdm2+/+ and Mdm2C305F/C305F mice need to 
be determined.  
p53 has been recognized as a tumor suppressor gene to control cell proliferation and 
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growth for a long time. However, p53 is conserved across species and even zebrafish has 
p53 protein. It is apparent however that zebrafish does not have tumors and therefore, what 
is the fundamental function of p53? It is likely that p53 also functions to protect organs or cells 
from daily stress, for instance metabolic stress. Given that in the Mdm2C305F mouse model, 
ribosomal stress signaling to p53 is disrupted by point mutation of Mdm2, this mouse can be a 
good model to study the role of p53 in response to metabolic stress. Studies designed to treat 
mice under metabolic stress, such as fasting, are in process.  
In summary, RP-Mdm2-p53 has been shown as a novel signaling pathway specifically in 
response to Myc induced lymphoma. Beyond that, more can be learned about the roles of this 
signaling pathway in response to daily stress by using the Mdm2C305F mouse model. 
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